TPX-4589

Summary

Tpx-4589 (CHEMBL5315025) is a phase-3 clinical-stage unknown; indicated across 1 condition including neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315025
Name	TPX-4589
Type	Unknown
Max phase	3

Also known as: Lm-302, Tpx-4589, TPX-4589

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1/PHASE2	3
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06351020	PHASE3	ACTIVE_NOT_RECRUITING	LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
NCT07385703	PHASE3	NOT_YET_RECRUITING	Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT05934331	PHASE2	RECRUITING	A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
NCT05994001	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
NCT06519591	PHASE2	RECRUITING	Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
NCT06587425	PHASE2	RECRUITING	The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07108504	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT07556640	PHASE2	RECRUITING	LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
NCT05161390	PHASE1/PHASE2	COMPLETED	Study of LM-302 in Patients With Advance Solid Tumors
NCT05188664	PHASE1/PHASE2	COMPLETED	Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
NCT05001516	PHASE1	COMPLETED	Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).